Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, Investigators TAX (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502–1512. https://doi.org/10.1056/NEJMoa040720

Article  CAS  PubMed  Google Scholar 

Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, Iversen P, Evans CP, Kim CS, Kimura G, Miller K, Saad F, Bjartell AS, Borre M, Mulders P, Tammela TL, Parli T, Sari S, van Os S, Theeuwes A, Tombal B (2017) Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 prevail study. Eur Urol 71(2):151–154. https://doi.org/10.1016/j.eururo.2016.07.032

Article  CAS  PubMed  Google Scholar 

Hong JH (2018) Pharmacokinetic/pharmacodynamic drug evaluation of enzalutamide for treating prostate cancer. Expert Opin Drug Metab Toxicol 14(3):361–369. https://doi.org/10.1080/17425255.2018.1440288

Article  CAS  PubMed  Google Scholar 

Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCafrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W et al (2019) Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. https://doi.org/10.1056/NEJMoa1903835

Hussain M, Fizazi K, Saad F et al (2018) Enzalutamide in men with nonmetastatic, castration- resistant prostate cancer. N Engl J Med 378:2465–2474

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alberto C, Konstantinou MP, Martinage C et al (2016) Enzalutamide induced acute generalized exanthematous pustulosis. J Dermatol Case Rep 10:35–38

Article  PubMed  PubMed Central  Google Scholar 

Lee S, Chung YJ, Kim BH et al (2009) Comparative pharmacokinetic evaluation of two formulations of bicalutamide 50-mg tablets: an open-label, randomized-sequence, single- dose, two-period crossover study in healthy Korean male volunteers. Clin Ther 31:3000–3008

Article  CAS  PubMed  Google Scholar 

Chodak G, Sharifi R, Kasimis B et al (1995) Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology. 46:849–855

Article  CAS  PubMed  Google Scholar 

Kolvenbag GJCM, Blackledge GRP (1996) Worldwide activity and safety of bicalutamide: a summary review. Urology 47:70–79

Article  CAS  PubMed  Google Scholar 

Fizazi K, Shore N, Tammela TL et al (2019) Darolutamide in nonmetastatic, castration- resistant prostate cancer. N Engl J Med 380:1235–1246

Article  CAS  PubMed  Google Scholar 

Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein JM, Stenzl A (2019) ARCHES: efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC). J Clin Oncol 37(15_suppl):5048–5048. https://doi.org/10.1200/JCO.2019.37.15_suppl.5048

Article  Google Scholar 

Saito-Sasaki N, Sawada Y, Okada E, Nakamura M (2018) Drug eruption caused by enzalutamide: a case and literature review of androgen receptor inhibitor related drug eruptions. Australas J Dermatol 59(2):e133–e134. https://doi.org/10.1111/ajd.12694

Article  PubMed  Google Scholar 

Alberto C, Konstantinou MP, Martinage C, Casassa E, Tournier E, Bagheri H et al (2016) Enzalutamide induced acute generalized exanthematous pustulosis. Dermatol Case Rep 10(2):35–38. https://doi.org/10.3315/jdcr.2016.1226

Article  Google Scholar 

Deng M, Chai H, Yang M, Wei X, Zhang W, Wang X, Li J, Wang Z, Chen H (2021) Stevens-Johnson syndrome caused by enzalutamide: a case report and literature review. Front Oncol 11:736975. https://doi.org/10.3389/fonc.2021.736975

Article  PubMed  PubMed Central  Google Scholar